Filing Flows › Angiodynamics (ANGO) › Guidance & outlook
Angiodynamics (ANGO) guidance and outlook
Angiodynamics (ANGO) raised some and lowered other parts of its guidance on Oct 8, 2026: Revenue $336M–$341M for ; Revenue +12% to +15% for ; Gross margin 54%–55% for ; EBITDA $13.0M–$16.0M for .
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | $336M–$341M | raised | |
| Revenue | +12% to +15% | lowered | |
| Gross margin | 54%–55% | reaffirmed | |
| EBITDA | $13.0M–$16.0M | raised | |
| EPS | −$0.29 to −$0.24 | reaffirmed |
From the earnings release filed Oct 8, 2026 (8-K on EDGAR).
Angiodynamics' latest quarter
Angiodynamics, Q1 FY27: revenue $80.9M (+7% year over year), operating margin -9.0%, net loss $7.1M, operating cash flow −$15.3M. The chart follows the revenue to costs, profit and cash.
Questions
Did Angiodynamics raise or lower its guidance?
Angiodynamics (ANGO) raised some and lowered other parts of its guidance on Oct 8, 2026: Revenue $336M–$341M for ; Revenue +12% to +15% for ; Gross margin 54%–55% for ; EBITDA $13.0M–$16.0M for .
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.